KRAS in non-small cell lung cancer

2 EU-approved indications in non-small cell lung cancer need a KRAS result: adagrasib (2nd line, advanced) and sotorasib (2nd line, advanced).

Line of therapy

Approved indications, Non-small cell lung cancer
DrugBiomarker requirementRegimenSettingConditions
KRAS mutation2
Adagrasib
Krazaticonditional
G12C
Monotherapy
2L
advanced
Disease progression after at least one prior systemic therapy
Sotorasib
Lumykrasconditional
G12C
Monotherapy
2L
advanced
After at least one prior line of systemic therapy

16 approvals for NSCLC need no biomarker and apply whatever the result. All approvals for NSCLC

See also

Label wording2

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Adagrasib (Krazati)
    KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.
  2. Sotorasib (Lumykras)
    LUMYKRAS as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and who have progressed after at least one prior line of systemic therapy.